The DOI matches its Crossref record; 76 of the 77 references it cites were found in a registry or an index.
New therapeutic approaches for metastatic thyroid carcinoma
Abstract
Treatment of metastatic differentiated thyroid cancer (DTC) includes the use of radioiodine and suppressive thyroid hormone treatment. A third of patients with distant metastases (who have radioiodine uptake, are younger than 40 years, have small metastases, and have well differentiated thyroid tumour) can be cured with radioiodine treatment. For other patients, there are no effective treatment modalities. However, the recent availability of molecularly targeted treatments has led to changes in the treatment strategy for DTC in patients with distant metastases, especially in those who are resistant to radioiodine treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“DePTC, which accounts for approximately 5-10% of patients with PTC, leads to resistance to traditional therapeutic strategies and worsens prognosis [9, 10, 29].”
From Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells (2017) · cites this paper as [29]
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Williams Textbook of Endocrinology
Melmed, S., & Polonsky, K. S. (2016) · Elsevier eBooks · doi:10.1016/c2013-0-15980-6 · Cited by 3,715
Increasing Incidence of Thyroid Cancer in the United States, 1973-2002
Davies, L., & Welch, H. G. (2006) · JAMA · doi:10.1001/jama.295.18.2164 · Cited by 3,379
International Histological Classification of Tumours
Weller, R. (1981) · Journal of Clinical Pathology · doi:10.1136/jcp.34.6.692-d · Cited by 2,047
Cooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Sherman, S. I., & Tuttle, R. M. (2006) · Thyroid · doi:10.1089/thy.2006.16.109 · Cited by 2,014
Pacini, F., Schlumberger, M. J., Dralle, H., Elisei, R., Smit, J. W. A., Wiersinga, W. M., & _, _. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02158 · Cited by 1,970
Self-citationDurante, C., Haddy, N., Baudin, É., Leboulleux, S., Hartl, D. M., Travagli, J. P., Caillou, B., Ricard, M., Lumbroso, J., de Vathaire, F., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2838 · Cited by 1,670
Self-citationTyrosine Kinases as Targets for Cancer Therapy
Krause, D. S., & Etten, R. A. V. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,402
HAY, I. D., Thompson, G. B., Grant, C. S., Bergstralh, E. J., Dvorak, C. E., Gorman, C. A., Maurer, M. S., McIver, B., Mullan, B. P., Oberg, A. L., et al. (2002) · World Journal of Surgery · doi:10.1007/s00268-002-6612-1 · Cited by 731
Nikiforova, M. N., Lynch, R. A., Biddinger, P. W., Alexander, E. K., Dorn, G. W., Tallini, G., Kroll, T. G., & Nikiforov, Y. E. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021907 · Cited by 711
Research works printed but not linked: 1
- Brierley, 2006, Bortezomib in patients with metastatic differentiated thyroid cancer: preliminary results of a multicenter phase II study. American Thyroid Association meeting, Phoenix, October 2006, Thyroid, 16, 857
Cited by
Sorted by citations
Guidelines for radioiodine therapy of differentiated thyroid cancer
Luster, M., Clarke, S. E., Dietlein, M., Laßmann, M., Lind, P., Oyen, W. J. G., Tennvall, J., & Bombardieri, E. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0883-1 · Cited by 725
“Another explanation for the low response rates may be that studies till now have not screened patients for retinoid receptor expression; use of such screening might increase response rates even as it narrows the treated population [ 10 , 100].”
BackgroundInfluentialCarr, L. L., Mankoff, D. A., Goulart, B., Eaton, K. D., Capell, P. T., Kell, E., Bauman, J. E., & Martins, R. G. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0994 · Cited by 425
Bible, K. C., Suman, V. J., Molina, J. R., Smallridge, R. C., Maples, W. J., Menefee, M. E., Rubin, J., Sideras, K., Morris, J. C., McIver, B., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70203-5 · Cited by 420
Thyroid carcinoma: molecular pathways and therapeutic targets
Nikiforov, Y. E. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.10 · Cited by 394
“Preliminary results of the trial in patients with progressive papillary carcinoma have shown minimal or partial response in some patients”
ResultMolecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis
Nikiforova, M. N., & Nikiforov, Y. E. (2007) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.8.1.83 · Cited by 277
B-Raf V600E and thrombospondin-1 promote thyroid cancer progression
Nucera, C., Porrello, A., Antonello, Z. A., Mekel, M., Nehs, M. A., Giordano, T. J., Gerald, D., Benjamin, L. E., Priolo, C., Puxeddu, E., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004934107 · Cited by 169
“There is no effective treatment for radioiodine-resistant metastatic disease; the 10-year survival rate in these cases is only 10% (2).”
BackgroundA Detailed Clinicopathologic Study of ALK-translocated Papillary Thyroid Carcinoma
Chou, A. S. Y., Fraser, S., Toon, C. W., Clarkson, A., Sioson, L., Farzin, M., Cussigh, C., Aniss, A. M., O’Neill, C. J., Watson, N., et al. (2014) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000368 · Cited by 109
“0289w Tumor size (mean [range]) (mm) 25 (7-67) 22 (0.”
ENDOCRINE TUMOURS: Approach to the patient with advanced differentiated thyroid cancer
Schlumberger, M. J., & Sherman, S. I. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0631 · Cited by 110
Self-citationNew targets and therapeutic approaches for endocrine malignancies☆
Fassnacht, M., Kreissl, M. C., Weismann, D., & Allolio, B. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.03.013 · Cited by 104
Ersahin, D., Doddamane, I., & Cheng, D. (2011) · Cancers · doi:10.3390/cancers3043838 · Cited by 104
“or slow progressive disease, low uptake of F-18 FDG, and repeated RAI treatment (response rate: 85%, with 96% of complete responses seen with a cumulative activity <600 mCi) [18].”
BackgroundBRAFV600E and Microenvironment in Thyroid Cancer: A Functional Link to Drive Cancer Progression
Nucera, C., Lawler, J., & Parangi, S. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3844 · Cited by 96
“are very low, and rational targeted therapies are being investigated (3).”
Identification of a Recurrent STRN/ALK Fusion in Thyroid Carcinomas
Pérot, G., Soubeyran, I., Ribeiro, A., Bonhomme, B., Savagner, F., Boutet-Bouzamondo, N., Hostein, I., Bonichon, F., Godbert, Y., & Chibon, F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087170 · Cited by 94
“In some cases, despite favorable outcomes late relapses are possible, and patients might die after local recurrence or metastases [6].”
BackgroundAn update on molecular biology of thyroid cancers
Ömür, Ö., & Baran, Y. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.12.007 · Cited by 95
“It was also shown o impair the growth of the ATC cell line xenografts in nude ice [228].”
BackgroundShaik, S., Nucera, C., Inuzuka, H., Gao, D., Garnaas, M., Frechette, G. M., Harris, L. N., Wan, L., Fukushima, H., Husain, A., et al. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20112446 · Cited by 93
Antitumor effects of anlotinib in thyroid cancer
Ruan, X., Shi, X., Dong, Q., Yu, Y., Hou, X., Song, X., Wei, X., Chen, L., & Gao, M. (2018) · Endocrine Related Cancer · doi:10.1530/erc-17-0558 · Cited by 91
Versari, A., Sollini, M., Frasoldati, A., Fraternali, A., Filice, A., Froio, A., Asti, M., Fioroni, F., Cremonini, N., Putzer, D., et al. (2013) · Thyroid · doi:10.1089/thy.2013.0225 · Cited by 91
“In addition, when radioiodine treatment is not effective, disease control becomes more difficult (1,2).”
Standard and Emerging Therapies for Metastatic Differentiated Thyroid Cancer
O’Neill, C. J., Oucharek, J. J., Learoyd, D., & Sidhu, S. B. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0190 · Cited by 77
Contemporary management of papillary carcinoma of the thyroid gland
Rosenbaum, M. A., & McHenry, C. R. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.9.3.317 · Cited by 73
Boufraqech, M., Kłubo-Gwieździńska, J., & Kebebew, E. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.10.001 · Cited by 71
“Although the majority of PTC cases have excellent prognoses and responses to therapy, 10– 15% of patients show signs of disease recurrence during follow up, which is associated with shorter overall survival [11].”
BackgroundPazopanib Enhances Paclitaxel-Induced Mitotic Catastrophe in Anaplastic Thyroid Cancer
Isham, C. R., Bossou, A. R., Negron, V. C., Fisher, K. E., Kumar, R., Marlow, L. A., Lingle, W. L., Smallridge, R. C., Sherman, E. J., Suman, V. J., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004358 · Cited by 69
“In particular, Sorrentino et al. reported aurora B overexpression in ATC relative to DTC and additionally found in vivo antitumor effects resulting from antisense aurora B treatment (24).”
BackgroundInfluentialMolecular Targeted Therapies of Aggressive Thyroid Cancer
Ferrari, S. M., Fallahi, P., Politti, U., Materazzi, G., Baldini, E., Ulisse, S., Miccoli, P., & Antonelli, A. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00176 · Cited by 69
“Approximately one-third of cancerrelated deaths are associated with neck lesions alone (20).”
BackgroundSpinal metastasis in thyroid cancer
Ramadan, S., Ugas, M. A., Berwick, R., Notay, M., Cho, H., Jerjes, W., & Giannoudis, P. V. (2012) · Head & Neck Oncology · doi:10.1186/1758-3284-4-39 · Cited by 66
“However, this cannot entirely explain the upward trend [8-10].”
BackgroundThyroid computed tomography imaging: pictorial review of variable pathologies
Saeedan, M. B., Aljohani, I. M., Khushaim, A., Bukhari, S. Q., & Elnaas, S. T. (2016) · Insights into Imaging · doi:10.1007/s13244-016-0506-5 · Cited by 65
Nipp, M., Elsner, M., Balluff, B., Meding, S., Sarioglu, H., Ueffing, M., Rauser, S., Unger, K., Höfler, H., Walch, A. K., et al. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0815-6 · Cited by 63
Targeting RET for thyroid cancer therapy
Lanzi, C., Cassinelli, G., Nicolini, V., & Zunino, F. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.10.033 · Cited by 61
New therapies for dedifferentiated papillary thyroid cancer
Fallahi, P., Mazzi, V., Vita, R., Ferrari, S., Materazzi, G., Galleri, D., Benvenga, S., Miccoli, P., & Antonelli, A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16036153 · Cited by 58
“about one third of cancer-related deaths are associated with the presence of neck lesions alone [9].”
BackgroundAnaplastic lymphoma kinase fusions: Roles in cancer and therapeutic perspectives (Review)
Cao, Z., Gao, Q., Fu, M., Ni, N., Pei, Y., & Ou, W. (2018) · Oncology Letters · doi:10.3892/ol.2018.9856 · Cited by 58
Nontoxic Diffuse and Nodular Goiter and Thyroid Neoplasia
Schlumberger, M.-J., Filetti, S., & HAY, I. D. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00014-6 · Cited by 57
Self-citationIten, F., Müller-Stich, B. P., Schindler, C., Rasch, H. F., Rochlitz, C. F., Oertli, D., Maëcke, H. R., Müller‐Brand, J., & Walter, M. A. (2009) · Cancer · doi:10.1002/cncr.24272 · Cited by 56
“However, no therapy is established in case of dedifferentiation,(3) and the median survival is only about 3 years after loss of iodine avidity.(2) Treatment with carboplatin, cisplatin, doxorubicin, epirubicin, or combined regimes has shown only rare responses with life-threatening toxicity or even drug-related death,…”
BackgroundBroecker‐Preuss, M., Müller, S. P., Britten, M. W., Worm, K., Schmid, K. W., Mann, K., & Führer, D. (2015) · BMC Cancer · doi:10.1186/s12885-015-1186-0 · Cited by 57
“In contrast, 10 to 15% of patients initially diagnosed with differentiated carcinomas experience recurrent disease [1,4,5].”
BackgroundImaging for staging and management of thyroid cancer
King, A. D. (2008) · Cancer Imaging · doi:10.1102/1470-7330.2008.0007 · Cited by 54
Piccardo, A., Trimboli, P., Foppiani, L., Treglia, G., Ferrarazzo, G., Massollo, M., Bottoni, G., & Giovanella, L. (2019) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-019-09491-2 · Cited by 52
Gunda, V., Bucur, O., Varnau, J., Borre, P. V., Bernasconi, M. J., Khosravi‐Far, R., & Parangi, S. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.78 · Cited by 51
“However, a subset of patients with anaplastic thyroid cancer (ATC) present with large invasive tumors and/or metastases, do not respond to any chemotherapeutic regimen and often die within months.(2) New data are emerging on the genetic or epigenetic changes, which seem to contribute to such dramatic worsening of the…”
BackgroundSalvatori, M., Biondi, B., & Rufini, V. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0066 · Cited by 51
Nucera, C., Goldfarb, M. R., Hodin, R. A., & Parangi, S. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.01.003 · Cited by 51
“Subsequent follow-up consists of yearly clinical exams, neck ultrasonography, and serum Tg level [55].”
BackgroundPiscazzi, A., Costantino, E., Maddalena, F., Natalicchio, M. I., Gerardi, A. M. T., Antonetti, R., Cignarelli, M., & Landriscina, M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3269 · Cited by 49
“The other two thirds of patients are deemed refractory to radioiodine therapy, and among them, the rate of progression is extremely variable (1).”
BackgroundThe BRAFV600E mutation: what is it really orchestrating in thyroid cancer?
Nucera, C., Lawler, J., Hodin, R. A., & Parangi, S. (2010) · Oncotarget · doi:10.18632/oncotarget.210 · Cited by 48
“Surgical treatment, thyroid suppressive therapy and radioiodine treatment in patients at high risk for recurrence is standard [2].”
BackgroundLapa, C., Werner, R. A., Schmid, J.-S., Papp, L., Zsótér, N., Biko, J., Reiners, C., Herrmann, K., Buck, A. K., & Bundschuh, R. A. (2014) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2014.12.006 · Cited by 50
“Whereas standard treatment including surgery and radioiodine is very effective and leads to survival times of more than 40 years [2], no sufficient therapy is established in case of dedifferentiationwhen local treatment is not feasible anymore due to the extension of the disease [3].”
BackgroundMicroRNA Expression Profiles in the Management of Papillary Thyroid Cancer
Lee, J. C., Gundara, J. S., Glover, A. R., Serpell, J. W., & Sidhu, S. B. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0135 · Cited by 45
Perspectives for Improved and More Accurate Classification of Thyroid Epithelial Tumors
Eszlinger, M., Krohn, K., Hauptmann, S., Dralle, H., Giordano, T. J., & Paschke, R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0201 · Cited by 42
“Already there are a number of different new molecular targeted drugs in clinical trials for thyroid cancer (57, 116).”
BackgroundMulti-targeted approach in the treatment of thyroid cancer
Chen, H. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s3062 · Cited by 40
Riwaldt, S., Bauer, J. W., Pietsch, J., Braun, M., Segerer, J., Schwarzwälder, A., Corydon, T. J., Infanger, M., & Grimm, D. G. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161226108 · Cited by 40
“have a significant toxicity and show only transient and limited response rates [5].”
BackgroundGEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma
Spano, J., Vano, Y.-A., Vignot, S., Rouge, T. D. L. M., Hassani, L., Mouawad, R., Ménégaux, F., Khayat, D., & Leenhardt, L. (2011) · Medical Oncology · doi:10.1007/s12032-011-0070-2 · Cited by 39
“Still, there is a lack of data and trials concerning the most recent drugs such as taxanes, gemcitabine, oxaliplatin, topoisomerase inhibitors, alone or in combination [5, 7].”
BackgroundThyroid Cancer: Current Molecular Perspectives
Giusti, F., Falchetti, A., Franceschelli, F., Marini, F., Tanini, A., & Brandi, M. L. (2010) · Journal of Oncology · doi:10.1155/2010/351679 · Cited by 39
“BAY 43-9006 has been tested on several types of human carcinomas including TCa, and the preliminary results showed a minimal or partial response in some patients [167].”
Molecular genetics of papillary thyroid carcinoma: great expectations...
Trovisco, V., Soares, P., Preto, A., Castro, P., Máximo, V., & Sobrinho-Simões, M. A. (2007) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302007000500002 · Cited by 37
Sunitinib inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF mutation
Jeong, W., Mo, J., Park, M. W., Choi, I. J., An, S.-Y., Jeon, E.-H., & Ahn, S. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.5.16303 · Cited by 37
“com Cancer Biology & Therapy 461 disease remains in 10–15% of the patients.(3) Ten-year survival rate drops to 25% when distant metastasis is detected.”
BackgroundShowalter, T. N., Siegel, B. A., Moley, J. F., Baranski, T., & Grigsby, P. W. (2008) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2008.0501 · Cited by 37
Yu, X.-M., Jaskula‐Sztul, R., Georgen, M. R., Aburjania, Z., Somnay, Y. R., LEVERSON, G. E., Sippel, R. S., Lloyd, R. V., Johnson, B. P., & Chen, H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1749 · Cited by 37
“Despite the excellent prognosis for most of the DTC patients, those with high-risk profiles may still suffer from disease progression, including tumor recurrence andmetastases, which poses a major challenge to the current treatment modality (14).”
BackgroundInfluentialSelective use of vandetanib in the treatment of thyroid cancer
Antonelli, A., Fallahi, P., Bari, F. D., Ferrari, S. M., Spisni, R., Materazzi, G., Miccoli, P., & Benvenga, S. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s72495 · Cited by 37
“However, 5% of patients have distant metastasis at the diagnosis or recurrent disease that cannot be treated with surgery and/or are resistant to RAI (because during progression, tumor cells lose RAI uptake ability).(66,67) For patients with metastatic disease, the NCCN Thyroid Carcinoma Panel recommends individualize…”
Enríquez, J. E., Muñoz-Montero, S. A., Imaz-Rosshandler, I., Huerta-Verde, A. J., Mejía, C., & Lemus, E. H. (2015) · BMC Genomics · doi:10.1186/s12864-015-1372-0 · Cited by 36
“On the other hand, ATC is an undifferentiated thyroid cancer, usually diagnosed at an advanced stage and thus not responding to chemotherapy; therefore frequently leading to a fatal prognosis [1].”
BackgroundWang, R., Yajun, C., Su, D., Gong, B., He, X., Zhou, X., Pang, Z., Cheng, L., Chen, Y., & Yao, Z. (2017) · Journal of Cancer · doi:10.7150/jca.21148 · Cited by 35
Update on Recent Developments in the Therapy of Differentiated Thyroid Cancer
Middendorp, M., & Grünwald, F. (2010) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2009.10.006 · Cited by 34
Ke, Y., & Xiang, C. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s187240 · Cited by 32
“Dedifferentiated tumors are more aggressive and had a worse outcome.(6,7) Currently, novel molecular targeting agents are gradually changing the natural history of traditional systemic chemotherapies of RAI-refractory thyroid cancer, which have showed improved progression-free survival in patients while the focus abla…”
BackgroundTsimberidou, A. M., Vaklavas, C., Wen, S., Hong, D. S., Wheler, J. J., Ng, C. S., Naing, A., Tse, S., Busaidy, N. L., Markman, M. M., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0743 · Cited by 31
“the disease is advanced or rapidly progressive (6).”
BackgroundInfluentialThyroid Cancer in Young Adults
Ying, A. K., Huh, W. W., Bottomley, S. J., Evans, D. B., & Waguespack, S. G. (2009) · Seminars in Oncology · doi:10.1053/j.seminoncol.2009.03.009 · Cited by 32
Coding Molecular Determinants of Thyroid Cancer Development and Progression
Valvo, V., & Nucera, C. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2018.10.003 · Cited by 31
Broecker‐Preuss, M., Becher-Boveleth, N., Müller, S. P., & Mann, K. (2016) · Cancer Cell International · doi:10.1186/s12935-016-0303-8 · Cited by 30
“However, in 10–15 % of patients initially diagnosed with differentiated carcinomas the tumor behaves aggressively and there is currently no effective treatment strategy since tumor dedifferentiation is accompanied by a reduction in radioiodine uptake and storage [4–6].”
BackgroundChen, H., Luo, D., Zhang, L., Lin, X., Luo, Q., Yi, H., Wang, J., Yan, X., Li, B., Chen, Y., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17398 · Cited by 29
“DePTC, which accounts for approximately 5-10% of patients with PTC, leads to resistance to traditional therapeutic strategies and worsens prognosis [9, 10, 29].”
BackgroundMechanisms of apoptosis in irradiated and sunitinib-treated follicular thyroid cancer cells
Grosse, J., Warnke, E., Wehland, M., Pietsch, J., Pöhl, F., Wise, P. M., Magnusson, N. E., Eilles, C., & Grimm, D. G. (2013) · APOPTOSIS · doi:10.1007/s10495-013-0937-0 · Cited by 29
“Because cytostatic chemotherapeutic substances are associated with significant toxicity and show only transient and limited response rates of 0–22 % [33],”
Refractory thyroid carcinoma: which systemic treatment to use?
Faugeras, L., Pirson, A., Donckier, J. E., Michel, L. A., Lemaire, J., Vandervorst, S., & D'Hondt, L. A. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017752853 · Cited by 29
Molecular Targeted Therapies for Patients with Refractory Thyroid Cancer
Chougnet, C., Brassard, M., Leboulleux, S., Baudin, É., & Schlumberger, M. J. (2010) · Clinical Oncology · doi:10.1016/j.clon.2010.04.008 · Cited by 27
“In 80% of papillary thyroid carcinomas, activating mutations have been found in genes encoding signalling molecules of the mitogen-activated protein (MAP) kinase pathway, and are believed to be the initiating event [5,6,24,25].”
BackgroundSelf-citationSurgical implications of B-RafV600E mutation in fine-needle aspiration of thyroid nodules
Mekel, M., Nucera, C., Hodin, R. A., & Parangi, S. (2010) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2009.08.029 · Cited by 25
A three-microRNA panel in serum as novel biomarker for papillary thyroid carcinoma diagnosis
Zou, X., Gao, F., Wang, Z., Zhang, H., Liu, Q., Jiang, L., Xin Min, Z. H. O. U., & Zhu, W. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001107 · Cited by 23
“Although most cases have a favorable prognosis after timely treatment, there is still a considerable proportion of patients with high-grade malignancy and poor overall survival.([19]) A previous study has validated the stable existence of miRNAs in blood circulation.”
BackgroundReferral bias in thyroid cancer surgery: Direction and magnitude
Machens, A., Hauptmann, S., & Dralle, H. (2007) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2007.07.006 · Cited by 23
Targeted therapies for advanced thyroid cancer
Puxeddu, E., Romagnoli, S., & Dottorini, M. E. (2010) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328340cf94 · Cited by 22
Spinal cord compression as initial presentation of metastatic occult follicular thyroid carcinoma
Khan, M. N., Sharfuzzaman, A., & Mostafa, M. G. (2014) · Journal of Neurosciences in Rural Practice · doi:10.4103/0976-3147.131661 · Cited by 21
“Solitary distant metastases of follicular thyroid carcinoma are very rarely amenable to complete resection and thus some local procedures to delay tumor progression and for symptom palliation are used, such as embolization, radio frequency, or cement injection and treatment with bisphosphonates.[24] However, both the…”
Zanotti‐Fregonara, P., Rubello, D., & Hindié, E. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.054163 · Cited by 20
“In these patients, new molecular targeted treatments may provide hope (13).”
BackgroundMohamed, A. F., González, J. M., & Fairchild, A. O. (2015) · Journal of Thyroid Research · doi:10.1155/2015/438235 · Cited by 19
“The focus is now on molecular targets like tyrosine kinase inhibitors (TKIs) and angiogenesis pathways [9, 14, 15].”
BackgroundInvestigational Therapies for Metastatic Thyroid Carcinoma
Tuttle, R. M., & Leboeuf, R. (2007) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2007.0055 · Cited by 20
“Because clinical trials have a small but definite risk of morbidity and mortality, proper patient selection is critical.(7) Furthermore, because trial outcomes are usually based on disease stabilization rather than dramatic reduction in tumor size, patients must have structurally progressive, measurable disease before…”
BackgroundInfluentialRadioiodine Imaging and Treatment in Thyroid Disorders
Griggs, W.-S., & Divgi, C. R. (2008) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2008.03.008 · Cited by 19
Standard and Emerging Therapeutic Approaches for Thyroid Malignancies
Brown, R. L. (2008) · Seminars in Oncology · doi:10.1053/j.seminoncol.2008.03.011 · Cited by 19
Cell death induction by the BH3 mimetic GX15-070 in thyroid carcinoma cells
Broecker‐Preuss, M., Viehof, J., Jastrow, H., Becher-Boveleth, N., Führer, D., & Mann, K. (2015) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-015-0186-x · Cited by 18
“due to their ability to take up radioiodine [5, 6].”
BackgroundImpact of Sunitinib on Human Thyroid Cancer Cells
Grosse, J., Warnke, E., Pöhl, F., Magnusson, N. E., Wehland, M., Infanger, M., Eilles, C., & Grimm, D. G. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350132 · Cited by 18
Wang, C., Diao, H., Ren, P., Wang, X., Wang, Y., & Zhao, W. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00640 · Cited by 17
“Although DTC is a tumor with a high degree of differentiation, disease recurrence or metastasis in DTC patients after surgery remains approximately 10–30% (10, 11).”
BackgroundReview: What Can Be Expected from Nuclear Medicine Tomorrow?
Barbet, J., Kraeber‐Bodéré, F., & Chatal, J. (2008) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2008.010-u · Cited by 17
Saha, S., Majumdar, R., Dighe, R. R., & Chakravarty, A. R. (2010) · Metallomics · doi:10.1039/c0mt00028k · Cited by 17
Age disparities in referrals to specialist surgical care for papillary thyroid cancer
Machens, A., & Dralle, H. (2009) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2009.07.008 · Cited by 17
“In papillary thyroid cancer, the interference of thyroid-stimulating hormone (TSH) and anti-thyroglobulin antibodies with thyroglobulin serum concentrations can diminish the relevance of thyroglobulin as a tumor marker.(12)”
BackgroundDíez, J. J., Iglesias, P., Alonso, T., & Grande, E. (2014) · Endocrine · doi:10.1007/s12020-014-0356-1 · Cited by 15
“classical chemotherapeutic agents have demonstrated limited activity with no impact on survival [3] and their use is no longer recommended in international guidelines [4].”
Distant metastases of differentiated thyroid cancer: diagnosis, treatment and outcome.
Toubert, M., Hindié, E., Rampin, L., AL-NAHHAS, A. M., & Rubello, D. (2007) · PubMed · Cited by 15
Targeted molecular therapies in thyroid carcinoma
Romagnoli, S., Moretti, S., Voce, P., & Puxeddu, E. (2009) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302009000900002 · Cited by 14
“Typically, these patients are younger, have well differentiated tumors, high radioiodine uptake, small metastases, location in the lung, stable or slow progressive disease and low uptake of fluorodeoxyglucose on 18-FDG PET scan (7).”
BackgroundInfluentialLu-177 labelled peptide treatment for radioiodine refractory differentiated thyroid carcinoma
Elboğa, U., Özkaya, M., Sayıner, Z. A., & Celen, Y. Z. (2016) · BMJ Case Reports · doi:10.1136/bcr-2015-213627 · Cited by 11
Ersahin, D., Doddamane, I., & Cheng, D. (2011) · Cancers · doi:10.3390/cancers3043858 · Cited by 12
Kaldrymides, P., Kostoglou‐Athanassiou, I., Gkountouvas, A., Veniou, E., & Ziras, N. (2010) · Endocrine · doi:10.1007/s12020-009-9290-z · Cited by 10
“High expression levels of tyrosine kinase receptors for fibroblast growth factor, epidermal growth factor, and vascular endothelial growth factor have also been observed in thyroid cancer [ 23 ].”
BackgroundAtallah, V., Hocquelet, A., Cao, C. D., Zerdoud, S., de la Fouchardière, C., Bardet, S., Italiano, A., Dierick-Gallet, A., Leduc, N., Bonichon, F., et al. (2016) · Thyroid · doi:10.1089/thy.2015.0648 · Cited by 10
“In those patients in whom progressive disease has been documented, classical chemo-therapeutic agents have demonstrated limited effectiveness (2).”
Huang, T., Cheng, Y.-K., Chen, T.-W., Hsu, Y.-C., Liu, E., & Chen, H. (2017) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-16-0100 · Cited by 10
“Doxorubicin is the most frequent chemotherapy agent, but only partial response rate of 22% can be achieved (14).”
Kinase inhibitors for refractory thyroid cancers
Schlumberger, M. J. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70226-6 · Cited by 10
Self-citationShi, P., Zhang, L., Shi, H., & Wu, Y. (2022) · Oncology Research and Treatment · doi:10.1159/000524489 · Cited by 9
Abuqbeitah, M., Demır, M., Kabasakal, L., Çavdar, İ., Uslu, L., Yeyin, N., Razavikhosroshahi, S., & Sönmezoğlu, K. (2018) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000000900 · Cited by 9
Targeted therapy in refractory thyroid cancer
Schlumberger, M. J. (2011) · European Journal of Cancer · doi:10.1016/s0959-8049(11)70190-3 · Cited by 9
Self-citationBroecker‐Preuss, M., Becher-Boveleth, N., Gall, S., Rehmann, K., Schenke, S., & Mann, K. (2015) · Cancer Cell International · doi:10.1186/s12935-015-0251-8 · Cited by 9
“Patients with recurrent disease have different outcomes due to the degree of dedifferentiation of their tumour and due to its ability to take up radioiodine [26, 28].”
BackgroundEmerging Therapies in Sight for the Fight against Dedifferentiated Thyroid Cancer
Benvenga, S. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2799 · Cited by 9
Prise en charge des cancers réfractaires de la thyroïde
Schlumberger, M. J. (2011) · Annales d Endocrinologie · doi:10.1016/j.ando.2011.03.020 · Cited by 8
Self-citationWu, Z., Cao, Y. Z., Jiang, X., Li, M., Wang, G., Yang, Y., & Lü, K. (2020) · Minerva Endocrinology · doi:10.23736/s0391-1977.18.02709-8 · Cited by 8
Zhang, W., Liu, D., Feng, C.-C., Zhou, C.-B., Zhan, C., Que, R., & Chen, L. (2014) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b1400124 · Cited by 7
“CT of the neck and chest and MRI of the spine, pelvis, and femurs can be useful to visualize metastatic foci (Baudin and Schlumberger, 2007).”
BackgroundRendl, G., Rettenbacher, L., Schweighofer-Zwink, G., Hehenwarter, L., & Pirich, C. (2020) · Hormone and Metabolic Research · doi:10.1055/a-1111-8927 · Cited by 7
Positron Emission Tomography/Computed Tomography in Thyroid Cancer
Bal, C., Chakraborty, D., & Khan, D. (2022) · PET Clinics · doi:10.1016/j.cpet.2021.12.004 · Cited by 7
A protective factor against lymph node metastasis of papillary thyroid cancer: Female gender
Shi, P., Yang, D., Liu, Y., Zhao, Z., Song, J., Shi, H., Wu, Y., & Jing, S. (2022) · Auris Nasus Larynx · doi:10.1016/j.anl.2022.10.001 · Cited by 7
Novel approaches in the treatment of thyroid cancer
Brown, R. L., & Cohen, E. E. W. (2008) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2008.01.002 · Cited by 7
Different CXCR4 Expression According to Various Histologic Subtype of Papillary Thyroid Carcinoma
Shin, D. Y., Kim, K. J., Ku, C. R., Lee, M. K., Jee, S. I., Chung, W. Y., & Lee, E. J. (2013) · Endocrine Pathology · doi:10.1007/s12022-013-9259-6 · Cited by 7
“However, 10–15 % of patients with DTC experience tumor recurrence and 5 % of them present with distant metastasis, leading to decreased 10-year survival rates of 49–68 and 25–42 %, respectively, in each case [5].”
BackgroundThe Association Between Lymph Node Metastasis and Molecular Markers in Differentiated Thyroid Cancer
Aydoğan, B. (2018) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2018.55 · Cited by 7
“Ten years survival rate decreases to 49-68% in node positive disease (6).”
Background
Metadata
- Authors
- Baudin, E., & Schlumberger, M.
- Affiliations
- Institut Gustave Roussy (FR)
- ORCID
- Schlumberger, Martin
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2007-02
- Volume
- 8
- Issue
- 2
- Pages
- 148-156
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2132185197
- Cited by
- 143
- References
- 77
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 1 · 2023: 2 · 2022: 6 · 2020: 6 · 2019: 1 · 2018: 9 · 2017: 4 · 2016: 11 · 2015: 13 · 2014: 11 · 2013: 7 · 2012: 8
- FWCI
- 2.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Keywords
- metastatic thyroid cancer, differentiated thyroid cancer, radioiodine therapy, targeted therapy, radioiodine resistance, distant metastasis, treatment options
- MeSH terms
- Humans, Iodine Radioisotopes, Thyroid Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
